Seeking Alpha

Following the FDA 's rejection of Qnexa and lorcaserin, Orexigen (OREX) makes it three for...

Following the FDA 's rejection of Qnexa and lorcaserin, Orexigen (OREX) makes it three for three, as the FDA issues a Complete Response Letter for Contrave, saying it wants another trial to rule out cardiovascular risk. After a halt, shares are down almost 70% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|